Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Complete Transurethral Resection on Oncologic Outcomes After Radiation Therapy for Muscle-Invasive Bladder Cancer.
Avolio PP, Kool R, Shayegan B, Marcq G, Black PC, Breau RH, Kim M, Busca I, Abdi H, Dawidek M, Uy M, Fervaha G, Cury FL, Sanchez-Salas R, Alimohamed N, Izawa J, Jeldres C, Rendon R, Siemens R, Kulkarni GS, Kassouf W. Avolio PP, et al. Among authors: abdi h. Int J Radiat Oncol Biol Phys. 2024 Aug 24:S0360-3016(24)03292-9. doi: 10.1016/j.ijrobp.2024.08.036. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39186955 Free article.
Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers.
Kool R, Marcq G, Breau RH, Black PC, Shayegan B, Kim M, Busca I, Abdi H, Dawidek MT, Uy M, Fervaha G, Cury FL, Alimohamed NS, Izawa JI, Jeldres C, Rendon R, Siemens DR, Kulkarni GS, Kassouf W. Kool R, et al. Among authors: abdi h. Eur Urol Oncol. 2023 Dec;6(6):597-603. doi: 10.1016/j.euo.2023.03.004. Epub 2023 Mar 31. Eur Urol Oncol. 2023. PMID: 37005214
Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis.
Kool R, Dragomir A, Kulkarni GS, Marcq G, Breau RH, Kim M, Busca I, Abdi H, Dawidek M, Uy M, Fervaha G, Cury FL, Alimohamed N, Izawa J, Jeldres C, Rendon R, Shayegan B, Siemens R, Black PC, Kassouf W. Kool R, et al. Among authors: abdi h. Eur Urol Oncol. 2024 Feb 6:S2588-9311(24)00040-3. doi: 10.1016/j.euo.2024.01.014. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38326142
The Impact of Histologic Subtypes on Clinical Outcomes After Radiation-Based Therapy for Muscle-Invasive Bladder Cancer.
Halstuch D, Kool R, Marcq G, Breau RH, Black PC, Shayegan B, Kim M, Busca I, Abdi H, Dawidek MT, Uy M, Fervaha G, Cury FL, Alimohamed NS, Jeldres C, Rendon R, Brimo F, Siemens DR, Kulkarni GS, Kassouf W, Izawa JI. Halstuch D, et al. Among authors: abdi h. J Urol. 2024 Nov;212(5):710-719. doi: 10.1097/JU.0000000000004160. Epub 2024 Jul 25. J Urol. 2024. PMID: 39051515
Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy.
Duivenvoorden WC, Daneshmand S, Canter D, Lotan Y, Black PC, Abdi H, van Rhijn BW, Fransen van de Putte EE, Zareba P, Koskinen I, Kassouf W, Traboulsi SL, Kukreja JE, Boström PJ, Shayegan B, Pinthus JH. Duivenvoorden WC, et al. Among authors: abdi h. J Urol. 2016 Dec;196(6):1627-1633. doi: 10.1016/j.juro.2016.06.017. Epub 2016 Jun 14. J Urol. 2016. PMID: 27312316
Editorial Comment.
Abdi H, Breau RH. Abdi H, et al. J Urol. 2019 Mar;201(3):518. doi: 10.1097/01.JU.0000553709.74021.24. J Urol. 2019. PMID: 30759693 No abstract available.
287 results